DA
FATE icon

Duality Advisers’s Fate Therapeutics FATE Stock Holding History

Duality Advisers’s Portfolio FATE Stock Details FATE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-38,536
Closed -$2.28M – 555
2021
Q3 		$2.28M Buy
+38,536
New +$3.02M 0.18% 228
2021
Q2 		– Sell
-52,731
Closed -$4.35M – 597
2021
Q1 		$4.35M Buy
+52,731
New +$5.05M 0.38% 74

Other funds holding FATE

RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Duality Advisers's FATE Position: Q4 2021 in Review

Duality Advisers sold out of Fate Therapeutics (FATE) in Q4 2021, closing a stake of 38,536 shares — an estimated $2.28M sold.

Duality Advisers first reported a position in FATE in Q1 2021 and held it in 2 quarters. The position peaked at $4.35M in Q1 2021. 250 funds tracked by Wall St. Rank hold FATE as of Q4 2021.

  • Duality Advisers reported no remaining Fate Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Duality Advisers sold 38,536 Fate Therapeutics shares in Q4 2021, an estimated $2.28M.
  • Duality Advisers first reported a position in Fate Therapeutics in Q1 2021 and held it in 2 quarters.
  • Duality Advisers's Fate Therapeutics position peaked at $4.35M in Q1 2021.
  • 250 funds tracked by Wall St. Rank held Fate Therapeutics as of Q4 2021.

Based on Duality Advisers's 13F filing for Q4 2021, filed 2 Feb 2022.